Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
Royal North Shore Hospital · Melanoma Institute Australia · +37 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
649
total citations
- FWCI
- 33.64
- Percentile
- 100%
- References
- 20
Citations per year
Authors
31- GVGeorgina V. LongCorresponding
Royal North Shore Hospital, Melanoma Institute Australia, The University of Sydney
- KTKeith T. Flaherty
Massachusetts General Hospital
- DSDaniil Stroyakovskiy
Moscow City Oncology Hospital №62
- HGHelen Gogas
Laiko General Hospital of Athens, National and Kapodistrian University of Athens
- ELE. Levchenko
Institute of Oncology NN Petrov
Topics & keywords
Topics
Keywords
- Dabrafenib
- Trametinib
- Medicine
- Internal medicine
- Clinical endpoint
- Melanoma
- Oncology
- Progression-free survival
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.